Olagunju M[au] - Search Results

Year	Number of Results
2015	1
2016	1
2017	1
2018	1
2019	1
2020	1
2021	4
2022	1
2023	0

1

Multiscale MD simulations of wild-type and sickle hemoglobin aggregation.

Olagunju MO, Loschwitz J, Olubiyi OO, Strodel B. Olagunju MO, et al. Proteins. 2022 Nov;90(11):1811-1824. doi: 10.1002/prot.26352. Epub 2022 May 18. Proteins. 2022. PMID: 35475513

2

Rational Drug Design of Peptide-Based Therapies for Sickle Cell Disease.

Olubiyi OO, Olagunju MO, Strodel B. Olubiyi OO, et al. Among authors: olagunju mo. Molecules. 2019 Dec 12;24(24):4551. doi: 10.3390/molecules24244551. Molecules. 2019. PMID: 31842406 Free PMC article. Review.

3

Design of Pd-Decorated SrTiO₃/BiOBr Heterojunction Materials for Enhanced Visible-Light-Based Photocatalytic Reactivity.

Olagunju MO, Zahran EM, Zeynaloo E, Shukla D, Cohn JL, Surnar B, Dhar S, Bachas LG, Knecht MR. Olagunju MO, et al. Langmuir. 2021 Oct 19;37(41):11986-11995. doi: 10.1021/acs.langmuir.1c01537. Epub 2021 Oct 5. Langmuir. 2021. PMID: 34608800

4

Atomically Resolved Characterization of Optically Driven Ligand Reconfiguration on Nanoparticle Catalyst Surfaces.

Olagunju MO, Liu Y, Frenkel AI, Knecht MR. Olagunju MO, et al. ACS Appl Mater Interfaces. 2021 Sep 22;13(37):44302-44311. doi: 10.1021/acsami.1c11256. Epub 2021 Sep 9. ACS Appl Mater Interfaces. 2021. PMID: 34499467

5

Dataset of AMBER force field parameters of drugs, natural products and steroids for simulations using GROMACS.

Loschwitz J, Jäckering A, Keutmann M, Olagunju M, Olubiyi OO, Strodel B. Loschwitz J, et al. Among authors: olagunju m. Data Brief. 2021 Mar 15;35:106948. doi: 10.1016/j.dib.2021.106948. eCollection 2021 Apr. Data Brief. 2021. PMID: 33855133 Free PMC article.

6

Computational Analysis of Physicochemical Factors Driving CYP2D6 Ligand Interaction.

Olubiyi OO, Olagunju MO, Obisesan AO. Olubiyi OO, et al. Among authors: olagunju mo. Curr Comput Aided Drug Des. 2017;13(1):39-47. doi: 10.2174/1573409912666160909092600. Curr Comput Aided Drug Des. 2017. PMID: 27632988

7

Novel inhibitors of the main protease enzyme of SARS-CoV-2 identified via molecular dynamics simulation-guided in vitro assay.

Loschwitz J, Jäckering A, Keutmann M, Olagunju M, Eberle RJ, Coronado MA, Olubiyi OO, Strodel B. Loschwitz J, et al. Among authors: olagunju m. Bioorg Chem. 2021 Jun;111:104862. doi: 10.1016/j.bioorg.2021.104862. Epub 2021 Mar 29. Bioorg Chem. 2021. PMID: 33862474 Free PMC article.

8

Structural Basis of Antisickling Effects of Selected FDA Approved Drugs: A Drug Repurposing Study.

Olubiyi OO, Olagunju MO, Oni JO, Olubiyi AO. Olubiyi OO, et al. Among authors: olagunju mo. Curr Comput Aided Drug Des. 2018;14(2):106-116. doi: 10.2174/1573409914666180129163711. Curr Comput Aided Drug Des. 2018. PMID: 29380703

9

High Throughput Virtual Screening to Discover Inhibitors of the Main Protease of the Coronavirus SARS-CoV-2.

Olubiyi OO, Olagunju M, Keutmann M, Loschwitz J, Strodel B. Olubiyi OO, et al. Among authors: olagunju m. Molecules. 2020 Jul 13;25(14):3193. doi: 10.3390/molecules25143193. Molecules. 2020. PMID: 32668701 Free PMC article.

10

Dopamine binds calmodulin during autoregulation of dopaminergic D2 receptor signaling through CaMKIIα-calmodulin complex.

Laoye BJ, Okurumeh OA, Obagaye OV, Olagunju MO, Bankole OO, Olubiyi OO, Ogundele OM. Laoye BJ, et al. Among authors: olagunju mo. J Recept Signal Transduct Res. 2016;36(3):271-7. doi: 10.3109/10799893.2015.1091476. Epub 2015 Oct 8. J Recept Signal Transduct Res. 2016. PMID: 26446938

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results